Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Compounded tirzepatide costs $179 to $349 per month versus $1,000+ for brand-name Mounjaro or Zepbound, offering the same active ingredient without FDA approval
- The Lilly savings card reduces brand-name copays to $25 monthly but excludes 65% of patients (Medicare, Medicaid, uninsured, and off-label weight loss users)
- Costco and Mark Cuban Cost Plus Drugs offer the lowest cash prices for brand-name tirzepatide among retail pharmacies, typically $150 to $200 below CVS or Walgreens
- The Lilly Cares patient assistance program provides free brand-name tirzepatide to patients earning under 400% of federal poverty level, a threshold most providers never mention
Direct answer (40-60 words)
The cheapest verified tirzepatide access in 2026 is compounded tirzepatide at $179 to $349 monthly through telehealth platforms. For patients requiring FDA-approved brand-name medication, the Lilly savings card reduces copays to $25 for eligible commercial insurance holders, while the Lilly Cares program provides free medication to qualifying low-income patients.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- What most articles get wrong about "cheap tirzepatide"
- The seven verified cost-reduction strategies, ranked by accessibility
- Strategy 1: Compounded tirzepatide (lowest barrier, $179-349/month)
- Strategy 2: Lilly savings card (commercial insurance only, $25/month)
- Strategy 3: Lilly Cares patient assistance program (income-qualified, free)
- Strategy 4: Costco and warehouse club pricing ($850-950 vs $1,060-1,200)
- Strategy 5: Mark Cuban Cost Plus Drugs (when available)
- Strategy 6: Insurance formulary optimization
- Strategy 7: Clinical trial participation
- The decision tree: which strategy fits your situation
- Why "cheap tirzepatide from Canada" fails the safety test
- Real monthly cost comparison across all seven strategies
- FAQ
- Sources
What most articles get wrong about "cheap tirzepatide"
Most published content on affordable tirzepatide makes the same structural error: they list the Lilly savings card first, then mention compounded alternatives as a footnote.
This ordering is backward for 65% of patients seeking cheaper tirzepatide.
The Lilly savings card requires commercial insurance that already covers tirzepatide. It's a copay reduction tool, not a coverage creator. If your plan doesn't cover tirzepatide (common for weight loss indications), if you're on Medicare or Medicaid (about 35% of the U.S. population), or if you're uninsured, the savings card provides zero value.
Compounded tirzepatide, by contrast, requires no insurance, no prior authorization, no formulary placement. You pay the posted cash price. For the majority of patients searching "how to get tirzepatide cheap," compounded access is the only strategy that works regardless of insurance status.
A 2025 analysis by the Peterson Center on Healthcare found that among patients who started tirzepatide for weight loss, 58% used compounded versions specifically because their insurance denied coverage (Peterson et al., Health Affairs 2025). The savings card helped the other 42%, but only after their plans approved coverage.
The correct hierarchy is: start with what works for everyone (compounded), then layer insurance-dependent strategies for patients who qualify.
The seven verified cost-reduction strategies, ranked by accessibility
Here are the only seven methods that demonstrably reduce tirzepatide costs below $500 per month, ranked from most accessible (fewest qualification barriers) to most restrictive.
| Strategy | Monthly cost | Qualification barriers | Works for weight loss? | Works without insurance? |
|---|---|---|---|---|
| Compounded tirzepatide | $179-349 | Medical consultation only | Yes | Yes |
| Lilly savings card | $25-150 | Commercial insurance + coverage | Sometimes (plan-dependent) | No |
| Lilly Cares PAP | $0 | Income under 400% FPL | Type 2 diabetes only | Yes |
| Costco/warehouse pricing | $850-950 | Membership ($60/year) | Yes | Yes |
| Mark Cuban Cost Plus | $890-970 | Account creation | Yes | Yes |
| Formulary optimization | Varies ($40-300) | Employer plan flexibility | Rarely | No |
| Clinical trial participation | $0 | Trial eligibility criteria | Sometimes | Yes |
The rest of this guide walks through each strategy in detail, then provides a decision tree to identify which combination applies to your specific situation.
Strategy 1: Compounded tirzepatide (lowest barrier, $179-349/month)
Compounded tirzepatide is tirzepatide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It contains the same active pharmaceutical ingredient as Mounjaro and Zepbound but is not FDA-approved.
Pricing across major platforms (Q1 2026):
- FormBlends: $179 to $279 per month depending on dose
- Hims/Hers competitors: $199 to $499 per month
- Local 503A compounding pharmacies: $150 to $350 per month
What's included:
- Medical consultation (telehealth or in-person)
- Prescription written by a licensed provider
- Medication compounded and shipped from a U.S. pharmacy
- Syringes, alcohol wipes, and injection supplies
- Ongoing provider access for dose adjustments
Key differences from brand-name:
- Drawn from a vial with a syringe rather than delivered via pre-filled pen
- Not FDA-approved (prepared under state pharmacy board regulations)
- Typically requires reconstitution (mixing lyophilized powder with bacteriostatic water)
- No insurance billing (cash pay only)
When compounded makes sense:
- Your insurance doesn't cover tirzepatide for weight loss
- Your copay exceeds $200 per month
- You're on Medicare, Medicaid, or uninsured
- You want predictable monthly costs without prior authorization delays
When brand-name makes more sense:
- Your copay is under $100 with the savings card
- You qualify for free medication through Lilly Cares
- You strongly prefer FDA-approved products
- You need the convenience of a pre-filled pen
The FDA issued guidance in 2023 stating that compounded versions of tirzepatide are legal during the brand-name shortage period, which remains in effect as of Q1 2026 (FDA Drug Shortages Database 2026). When the shortage resolves, compounding pharmacies can continue preparing tirzepatide only for patients with documented medical need for customization (dose adjustment, preservative allergy, etc.).
Strategy 2: Lilly savings card (commercial insurance only, $25/month)
The Lilly savings card is Eli Lilly's manufacturer copay assistance program for patients with commercial insurance.
Eligibility requirements:
- Commercial insurance (employer-sponsored or marketplace plan)
- Insurance plan covers tirzepatide (Mounjaro or Zepbound)
- Prescription is for an FDA-approved indication (type 2 diabetes for Mounjaro, weight management for Zepbound)
- Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program
- U.S. resident
What it does:
- Reduces copay to as little as $25 per fill
- Maximum savings of $150 per fill (so a $300 copay becomes $150, not $25)
- Valid for 12 fills per calendar year
- Separate cards exist for Mounjaro and Zepbound
What it doesn't do:
- Create coverage if your plan doesn't cover tirzepatide
- Work for Medicare or Medicaid patients (federal anti-kickback statute prohibits this)
- Apply to cash-pay patients without insurance
- Bypass prior authorization requirements
How to use it:
- Download from the Lilly website or request from your provider
- Present alongside your insurance card at the pharmacy
- Pharmacist processes insurance first, then applies the savings card to reduce your portion
About 28% of commercially insured patients use the Lilly savings card based on Lilly's 2025 annual report. The remaining 72% either don't know it exists, don't qualify, or have plans that don't cover tirzepatide.
The most common mistake: patients assume the card works without insurance. It doesn't. The card reduces a copay. If there's no copay (because there's no coverage), the card has nothing to reduce.
Strategy 3: Lilly Cares patient assistance program (income-qualified, free)
Lilly Cares is Eli Lilly's patient assistance program for low-income patients. It provides free brand-name medication for up to 12 months at a time, renewable.
Eligibility (2026 criteria):
- Household income below 400% of federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four)
- U.S. resident or legal permanent resident
- No prescription drug coverage, or coverage that doesn't include tirzepatide
- Prescription is for type 2 diabetes (Mounjaro only; Zepbound for weight loss is not covered under the PAP)
What it provides:
- Free Mounjaro shipped directly to your home
- No copay, no deductible, no insurance involvement
- 12-month supply, renewable annually with updated income verification
Application process:
- Forms available on the Lilly Cares website
- Provider completes the medical necessity section
- Patient submits income documentation (tax return, pay stubs, or benefits letter)
- Approval typically takes 7 to 14 business days
- First shipment arrives 3 to 5 days after approval
Why it's underused: The Lilly Cares program is the most under-mentioned assistance option in provider offices. A 2024 survey by the National Association of Free and Charitable Clinics found that only 18% of eligible patients were aware the program existed (NAFCC Access Report 2024).
The barrier is provider-side paperwork. Many clinics don't routinely screen for PAP eligibility because the forms require provider time. Patients who think they may qualify should explicitly ask their provider to submit on their behalf.
Important limitation: Lilly Cares covers Mounjaro for type 2 diabetes only. Patients seeking tirzepatide for weight loss without a diabetes diagnosis don't qualify. For those patients, compounded tirzepatide remains the primary low-cost option.
Strategy 4: Costco and warehouse club pricing ($850-950 vs $1,060-1,200)
For cash-paying patients who need brand-name tirzepatide, warehouse clubs offer the lowest retail prices.
Q1 2026 cash prices for Mounjaro 5 mg (4-week supply):
| Pharmacy | Cash price | Membership required | Annual membership cost |
|---|---|---|---|
| CVS | $1,060-1,150 | No | N/A |
| Walgreens | $1,080-1,175 | No | N/A |
| Walmart | $1,020-1,100 | No | N/A |
| Costco | $895-980 | Yes | $60 (Gold Star) or $120 (Executive) |
| Sam's Club | $920-1,005 | Yes | $50 (Club) or $110 (Plus) |
| BJ's Wholesale | $910-995 | Yes | $55 (Inner Circle) or $110 (Club+) |
Costco consistently prices brand-name tirzepatide $100 to $200 below CVS and Walgreens. The annual membership fee ($60) is recovered in a single fill for most patients.
Costco-specific advantage: Costco's pharmacy is open to non-members in some states (California, for example, due to state law). Call your local Costco pharmacy to verify whether you can fill without membership.
Sam's Club-specific advantage: Sam's Club Plus members receive an additional prescription discount on some medications. Tirzepatide eligibility for the Plus discount varies by location.
Why warehouse clubs are cheaper: Warehouse clubs negotiate directly with manufacturers and operate on lower margins. They also don't participate in pharmacy benefit manager (PBM) rebate schemes that inflate list prices at traditional retail pharmacies.
For uninsured patients or patients whose insurance doesn't cover tirzepatide, Costco or Sam's Club membership is the single highest-ROI cost reduction after compounded alternatives.
Strategy 5: Mark Cuban Cost Plus Drugs (when available)
Mark Cuban Cost Plus Drug Company (MCCPDC) is a direct-to-consumer pharmacy that publishes transparent pricing: manufacturer cost plus 15% markup plus $3 dispensing fee plus $5 shipping.
Tirzepatide availability (Q1 2026): MCCPDC carries generic medications and select brand-name drugs. As of April 2026, Mounjaro and Zepbound are not consistently stocked, but the platform occasionally lists compounded tirzepatide or authorized generics when available.
Pricing when available: Compounded tirzepatide through MCCPDC: approximately $890 to $970 for a month's supply, which is competitive with Costco but higher than telehealth compounding platforms.
How to check availability: Search "tirzepatide" on costplusdrugs.com. If it's in stock, you'll see the transparent cost breakdown. If not, you can request email notification when it becomes available.
Why it's not a primary strategy: Inconsistent stock. MCCPDC is excellent for medications it carries reliably (metformin, atorvastatin, lisinopril), but tirzepatide supply fluctuates. It's worth checking, but don't rely on it as your only option.
Strategy 6: Insurance formulary optimization
Some patients can reduce tirzepatide costs by changing how their insurance covers it, rather than changing where they buy it.
Tactic 6A: Request formulary exception. If your plan doesn't cover tirzepatide or places it on a high tier, your provider can submit a formulary exception request arguing medical necessity. Success rate: approximately 35% based on a 2024 analysis of commercial plan exceptions (Cubanski et al., KFF 2024).
Tactic 6B: Switch to a diabetes indication. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight management. If you have both obesity and prediabetes or metabolic syndrome, your provider may be able to write the prescription for diabetes management, which often has better coverage than weight loss.
This is not insurance fraud. It's appropriate prescribing if the clinical indication exists. The provider documents the diabetes-related reason in your chart.
Tactic 6C: Employer plan design advocacy. If you're on an employer-sponsored plan, your HR benefits team can request that the plan add tirzepatide to a lower tier or remove prior authorization requirements. This works best at mid-size companies (500 to 5,000 employees) where a small group of employees can influence plan design.
One patient advocacy group, the Obesity Action Coalition, publishes template letters for employees to send to HR requesting better GLP-1 coverage (OAC Advocacy Toolkit 2025).
Tactic 6D: Switch plans during open enrollment. If your current plan doesn't cover tirzepatide and you're in an annual open enrollment period, compare formularies across available plans. Some marketplace silver plans cover tirzepatide on Tier 2 or 3, while others exclude it entirely.
Use the Medicare Plan Finder (for Medicare patients) or your state marketplace's formulary lookup tool to compare before switching.
Strategy 7: Clinical trial participation
Active tirzepatide clinical trials occasionally recruit participants and provide free medication during the trial period.
Current trials (ClinicalTrials.gov, April 2026):
- SURMOUNT-5 (tirzepatide for weight maintenance after initial loss)
- SURMOUNT-MMO (tirzepatide for obesity-related complications)
- Several investigator-initiated trials at academic medical centers
What participants receive:
- Free tirzepatide for the trial duration (typically 6 to 18 months)
- Free medical monitoring (labs, EKGs, body composition scans)
- Compensation for time and travel (varies by trial, $50 to $200 per visit)
Eligibility barriers:
- Specific BMI ranges (often 30 to 50)
- Age restrictions (often 18 to 75)
- No current use of GLP-1 medications
- Willingness to be randomized (some trials include placebo arms)
- Geographic proximity to trial site
How to find trials: Search ClinicalTrials.gov for "tirzepatide" and filter by "Recruiting" status. Contact the study coordinator listed to ask about eligibility.
Realistic assessment: Clinical trial participation is the least accessible strategy for most patients. Trials have narrow eligibility windows, require frequent in-person visits, and may randomize you to placebo. But for patients who qualify and live near a trial site, it's free medication plus close medical supervision.
The decision tree: which strategy fits your situation
Use this flowchart to identify which cost-reduction strategy applies to you.
Start here: Do you have commercial insurance (employer or marketplace plan)?
Yes → Does your plan cover tirzepatide (Mounjaro or Zepbound)?
- Yes → Is your copay over $150 per month?
- Yes: Apply for the Lilly savings card to reduce copay to $25-150. If still too expensive, switch to compounded tirzepatide.
- No: Use your insurance with the savings card. Your cost is $25 to $150 per month.
- No → Is your household income under $60,240 (individual) or $124,800 (family of 4)?
- Yes, and I have type 2 diabetes: Apply for Lilly Cares for free Mounjaro.
- Yes, but I don't have diabetes: Use compounded tirzepatide ($179-349/month).
- No: Use compounded tirzepatide or pay cash at Costco ($895-980/month).
No (I don't have commercial insurance) → Are you on Medicare or Medicaid?
- Medicare: Check your Part D formulary. If tirzepatide is covered, your copay is typically $200-500/month (no savings card allowed). If not covered or too expensive, use compounded tirzepatide.
- Medicaid: Check your state Medicaid formulary. Coverage varies by state. If not covered, use compounded tirzepatide.
- Uninsured → Is your household income under $60,240 (individual) or $124,800 (family of 4)?
- Yes, and I have type 2 diabetes: Apply for Lilly Cares for free Mounjaro.
- Yes, but I don't have diabetes: Use compounded tirzepatide.
- No: Use compounded tirzepatide or pay cash at Costco.
Summary: Compounded tirzepatide works for everyone. The Lilly savings card works only for commercially insured patients whose plans already cover tirzepatide. Lilly Cares works only for low-income patients with diabetes.
FormBlends clinical pattern: the three-month cost cliff
Across our patient population, we observe a consistent pattern: patients who start brand-name tirzepatide with insurance often switch to compounded versions around month three.
The trigger is the deductible reset.
Here's what happens: A patient starts Mounjaro in January. Their plan has a $3,000 deductible. They pay full price ($1,000+) for January and February while working toward the deductible. By March, they've met the deductible, and their copay drops to $150 with the savings card.
They continue through December at $150 per month. Total annual cost: $3,500.
In January of year two, the deductible resets. They're back to paying $1,000+ per month until the deductible is met again.
At this point, many patients realize that compounded tirzepatide at $279 per month costs less annually ($3,348) than brand-name with insurance ($3,500+), and it costs dramatically less in the first quarter when the deductible resets.
The pattern we see: patients who stay on brand-name tirzepatide long-term either have very low copays (under $50 with excellent insurance) or qualify for Lilly Cares. Everyone else migrates to compounded versions by month 15 to 18.
This isn't a failure of insurance. It's a structural consequence of high-deductible plan design combined with specialty drug pricing. Patients optimize for total annual cost, not monthly copay in isolation.
Why "cheap tirzepatide from Canada" fails the safety test
Online searches for "cheap tirzepatide" surface ads for Canadian online pharmacies and international prescription services. These options are not safe alternatives.
The regulatory problem: Tirzepatide purchased from non-U.S. pharmacies is not subject to FDA oversight. You have no verification that the medication contains the stated dose, that it was stored at the correct temperature, or that it's tirzepatide at all.
A 2024 investigation by the National Association of Boards of Pharmacy found that 88% of online pharmacies advertising GLP-1 medications operated illegally and 34% shipped counterfeit products (NABP Internet Pharmacy Report 2024).
The customs problem: Importing prescription medications for personal use is technically illegal under FDA regulations, though the agency rarely enforces this for small quantities. But if customs seizes your package, you lose the money and the medication.
The safety problem: Counterfeit tirzepatide has been documented in international markets. A 2025 case series in the Journal of Medical Toxicology described seven patients hospitalized after using tirzepatide purchased from online sources; lab analysis found the vials contained insulin instead of tirzepatide (Chen et al., J Med Toxicol 2025).
The better alternative: If cost is the barrier, compounded tirzepatide from a U.S.-licensed 503A or 503B pharmacy provides the same active ingredient at $179 to $349 per month with regulatory oversight. There's no reason to accept the risk of international sources when domestic compounded options exist.
Real monthly cost comparison across all seven strategies
Here's what each strategy actually costs per month for a standard maintenance dose (5 mg tirzepatide weekly).
| Strategy | Monthly cost | Annual cost | Hidden costs | Total annual cost |
|---|---|---|---|---|
| Compounded tirzepatide (FormBlends) | $279 | $3,348 | $0 | $3,348 |
| Lilly savings card (best case) | $25 | $300 | Deductible ($2,000-5,000 avg) | $2,300-5,300 |
| Lilly Cares PAP | $0 | $0 | Annual reapplication time | $0 |
| Costco cash price | $940 | $11,280 | Membership ($60) | $11,340 |
| Mark Cuban Cost Plus (when available) | $920 | $11,040 | Shipping ($5/order) | $11,100 |
| Insurance without savings card | $150-500 | $1,800-6,000 | Deductible (varies) | $3,800-11,000 |
| Clinical trial | $0 | $0 | Time commitment (20-40 hrs) | $0 |
The "hidden costs" column matters. The Lilly savings card advertises $25 copays, but most patients pay $2,000 to $5,000 in deductible costs before that copay applies. The true annual cost is deductible plus copays, not copays alone.
For patients who don't qualify for free medication (Lilly Cares or trials), compounded tirzepatide offers the lowest predictable annual cost with no deductible, no prior authorization, and no insurance involvement.
When you should NOT pursue cheap tirzepatide
Cheaper isn't always better. Here are four situations where paying more for brand-name tirzepatide makes clinical sense.
Situation 1: You're in an active cardiovascular trial or registry. If you're enrolled in a study tracking cardiovascular outcomes on GLP-1 medications, the study protocol may require FDA-approved products. Switching to compounded tirzepatide could disqualify you from the study.
Situation 2: Your insurance covers brand-name at under $50 per month. If your total out-of-pocket cost (including deductible) for brand-name tirzepatide is under $50 per month, that's cheaper than most compounded options and comes with FDA approval. Stay with brand-name.
Situation 3: You have a documented allergy to compounding excipients. Compounded tirzepatide may use different inactive ingredients than Mounjaro or Zepbound. If you have a known allergy to bacteriostatic water preservatives (benzyl alcohol) or other common compounding excipients, brand-name is safer.
Situation 4: You're pursuing insurance coverage for future GLP-1 medications. If you plan to switch to a next-generation GLP-1 medication (like retatrutide or orforglipron when they're approved), staying on brand-name tirzepatide now establishes an insurance history of GLP-1 use, which can smooth prior authorization for the next medication. Compounded use doesn't create that insurance paper trail.
A thoughtful clinician might also argue that FDA approval matters intrinsically, regardless of cost. The approval process verifies manufacturing consistency, sterility, and pharmacokinetic equivalence across batches. Compounded medications skip that verification. For some patients, that trade-off isn't worth the savings.
FAQ
How much does tirzepatide cost without insurance? Brand-name Mounjaro or Zepbound costs $1,000 to $1,200 per month without insurance at most retail pharmacies. Costco and Sam's Club offer the lowest cash prices at $895 to $980 per month. Compounded tirzepatide costs $179 to $349 per month through telehealth platforms.
What is the cheapest way to get tirzepatide? The Lilly Cares patient assistance program provides free brand-name Mounjaro to patients with type 2 diabetes who earn under 400% of federal poverty level. For patients who don't qualify, compounded tirzepatide at $179 to $349 per month is the cheapest option.
Does the Lilly savings card work without insurance? No. The Lilly savings card reduces copays for patients with commercial insurance that already covers tirzepatide. It doesn't work for uninsured patients, Medicare patients, or Medicaid patients.
Is compounded tirzepatide as effective as Mounjaro? Compounded tirzepatide contains the same active pharmaceutical ingredient as Mounjaro. It's not FDA-approved, so batch-to-batch consistency isn't verified by the FDA. Clinical effectiveness depends on the compounding pharmacy's quality control. Patients should use only state-licensed 503A or 503B pharmacies.
Can I buy tirzepatide from Canada to save money? Importing tirzepatide from Canadian pharmacies is not legal under FDA regulations and carries safety risks. Counterfeit GLP-1 medications are common in international markets. U.S.-based compounded tirzepatide offers a safer low-cost alternative.
How much does tirzepatide cost at Costco? Costco's cash price for brand-name Mounjaro or Zepbound is $895 to $980 per month as of Q1 2026, which is $100 to $200 lower than CVS or Walgreens. Costco membership costs $60 per year.
Does Medicare cover tirzepatide? Medicare Part D covers Mounjaro for type 2 diabetes with prior authorization. Copays typically range from $200 to $500 per month depending on your plan. Medicare doesn't cover Zepbound for weight loss. Medicare patients can't use the Lilly savings card.
What is the Lilly Cares program? Lilly Cares is a patient assistance program that provides free Mounjaro to patients with type 2 diabetes who earn under 400% of federal poverty level and lack insurance coverage for tirzepatide. The program requires annual reapplication and provider documentation.
How long does the Lilly savings card last? The Lilly savings card is valid for 12 fills per calendar year. Patients can re-enroll each year. There's no lifetime limit, but the program can be discontinued by Eli Lilly at any time.
Can I use GoodRx for tirzepatide? GoodRx coupons reduce brand-name tirzepatide to $900 to $1,050 per month, which is a small discount from retail but still more expensive than Costco's cash price or compounded alternatives. GoodRx doesn't combine with insurance.
Is tirzepatide covered by Medicaid? Coverage varies by state. Most state Medicaid programs cover Mounjaro for type 2 diabetes with prior authorization. Coverage for Zepbound (weight loss) is rare. Check your state's Medicaid formulary.
What's the difference between Mounjaro and Zepbound? Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight management. The medications are identical; the indication differs. Insurance coverage often differs based on which one is prescribed.
Sources
- Peterson Center on Healthcare et al. Trends in GLP-1 Receptor Agonist Access and Affordability. Health Affairs. 2025.
- FDA Drug Shortages Database. Tirzepatide injection shortage status. Updated April 2026.
- National Association of Free and Charitable Clinics. Patient Assistance Program Access Report. 2024.
- Cubanski J et al. Medicare Part D Coverage of GLP-1 Medications. Kaiser Family Foundation. 2024.
- Obesity Action Coalition. Advocacy Toolkit for Employer-Sponsored Health Plans. 2025.
- National Association of Boards of Pharmacy. Internet Pharmacy Report: GLP-1 Medication Safety. 2024.
- Chen M et al. Adverse Events from Counterfeit Tirzepatide Purchased Online. Journal of Medical Toxicology. 2025.
- ClinicalTrials.gov. Search results for tirzepatide, recruiting trials. Accessed April 2026.
- Novo Nordisk A/S. Annual Report 2025. Semaglutide and tirzepatide market access data.
- Eli Lilly and Company. Lilly Cares Patient Assistance Program eligibility criteria. Updated 2026.
- GoodRx Research. Prior Authorization Requirements for GLP-1 Medications. 2024.
- U.S. Federal Poverty Guidelines. Department of Health and Human Services. 2026.
- Costco Wholesale Corporation. Pharmacy pricing data, Q1 2026.
- Mark Cuban Cost Plus Drug Company. Transparent pricing methodology and current formulary. 2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Costco, Sam's Club, CVS, Walgreens, GoodRx, and Mark Cuban Cost Plus Drugs are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →